OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - BRISTOL-MYERS SQUIBB | Market Closed - Deutsche Boerse AG 20:39:18 28/06/2024 BST | ||
| 4.08 EUR | -.--% |
|
| 1 month | -0.97% | ||
| 3 months | +41.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 4.08 | -.--% |
| 27/06/24 | 4.08 | +2.26% |
| 26/06/24 | 3.99 | -0.50% |
| 25/06/24 | 4.01 | -.--% |
| 24/06/24 | 4.01 | -1.47% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 08:39 pm
More quotesStatic data
| Product type | Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SF7KAU |
| ISIN | DE000SF7KAU4 |
| Date issued | 02/08/2021 |
| Strike | 85.31 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.12 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.18 € |
|---|---|
| Lowest since issue | 0.62 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.53
USD
Average target price
53.19
USD
Spread / Average Target
+28.09%
- Stock Market
- Certificates
- Certificat
